Trial Profile
A randomized, open-label, multicenter trial to assess the efficacy of subcutaneous secukinumab after twelve weeks of treatment, and to assess the long-term safety, tolerability and efficacy in subjects from 6 to less than 18 years of age with moderate to severe chronic plaque psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 14 Feb 2024 This trial has been completed in Poland, according to the European Clinical Trials Database record.
- 08 Oct 2023 This trial has been completed in Germany, according to the European Clinical Trials Database record.
- 06 Oct 2023 This trial has been completed in Czech Republic, according to the European Clinical Trials Database record.